Abstract
The effects of intracerebroventricular (ICV) and intravenous (IV) administration of human pancreatic growth hormone-releasing factor (hpGRF) on gastro-intestinal motility were examined in fasted and fed conscious dogs equipped with chronically implanted strain-gages on the antrum and the jejunum. During the fasted state, hpGRF injected ICV at 0.1 μg·kg −1 or IV at 0.5 μg·kg −1 did not affect the cyclic occurrence of the migrating motor complex (MMC). This pattern was normally disrupted for 8–10 hours by a daily standard meal. Injected ventricularly (0.1 μg·kg −1) but not intravenously (0.5 μg·kg −1) 10–15 min after the daily meal, hpGRF significantly reduced ( p<0.01) the duration of the jejunal fed pattern ( 2.0±1.4 vs. 8.4±1.1 hours for control) but not that of the stomach. This effect persisted when hpGRF (0.1 μg·kg −1 ICV) was administered after indomethacin (2 mg·kg −1 IM), naltrexone (0.1 mg·kg −1 IV) or domperidone (1 mg·kg −1 IV) but was abolished by a previous IV injection of metoclopramide (1 mg·kg −1). It was concluded that hpGRF is able to act centrally to control the pattern of jejunal motility in fed but not in fasted dog, its effect being probably mediated through dopaminergic pathways.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
